Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary®): Results of a Nationwide Dose Conversion Survey
Table 1
Respondent practice characteristics.
n (%)
Specialty
GN treating some PD pts
4 (4)
GN treating mostly PD pts
1 (1)
MDS treating some PD pts
3 (3)
MDS treating mostly PD pts
82 (91)
Type of practice
Academic institution
48 (53)
Community-based facility
20 (22)
Community-based with academic affiliation
22 (24)
Years in practice
<10
33 (37)
11–20
38 (42)
>20
19 (21)
Average no. of PD pts seen/month
<10
0 (0)
11–50
10 (11)
51–100
39 (43)
>100
41 (46)
CD-LD IR Rx/month
<10
3 (3)
11–50
20 (22)
51–100
45 (50)
>100
22 (24)
CD-LD ER Rx/month
<10
8 (9)
11–50
62 (69)
51–100
14 (15)
>100
6 (7)
GN = general neurologist; MDS = movement disorder specialist; PD = Parkinson’s disease; CD-LD IR = carbidopa-levodopa immediate-release; CD-LD ER = carbidopa-levodopa extended-release.
